Local delivery methods into the CNS

Minimally Invasive Neurosurgery

Volumn , Issue , 2005, Pages 297-316

  Vogel, Timothy W ^a   Bruce, Jeffrey N ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33746511870     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1385/1-59259-899-4:297     Document Type: Chapter

References (97)

1. Buahin K, Brem H, et al. Interstitial chemotherapy of experimental brain tumors: Comparison of intratumoral injection versus polymeric controlled release. J Neurooncol 1995;26:103-110.
2. Groothius DR. The blood-brain and blood- Tumor barriers: A review of strategies for increasing drug delivery. Neurooncology 2000;2:45-59.
3. Giese A, Westphal M. Treatment of malignant glioma: A problem beyond the margins of resection. J Cancer Res Clin Oncol 2001;127:217-225.
4. Tamargo RJ, Brem H. Drug delivery to the central nervous system: A review. Neurosurg Q 1992;2:259-279.
5. Walter KA, Tamargo RJ, et al. Intratumoral chemotherapy. Neurosurgery 1995;37: 1129-1145.
6. Tashiro T, Yoshida J, et al. Reinforced cytotoxicity of lymphokine- Activated killer cells toward glioma cells by transfection with the tumor necrosis factor- Alpha gene. J Neurosurg 1993;78:252-256.
7. Fung LK, Ewend MG, et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 1998;58:672-684.
8. Sipos EP, Tyler B, et al. optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacology 1997;39:383-389.
9. Ewend MG, Williams JA, et al. local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. Cancer Res 1996;56:5217-5223.
10. Brem H, Mahaley MS, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991;74:441-446.
11. Brem H, Tamargo RJ, et al. biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg 1994;80:283-290.
12. Tomita T. Interstitial chemotherapy for brain tumors: review. J Neurooncol 1991;10: 57-74.
13. Grossman SA, Reinhard C, et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 1992;76:640-647.
14. Merchant RE, McVicar DW, et al. Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon- Alpha. results of a phase I clinical trial. J Neurooncol 1992;12:75-83.
15. Chamberlain MC, Kormanik PA, et al. complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997; 87:694-699.
16. Sanberg DI, Bilsky MH, et al. ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 2000;47:49-55.
17. Park DY, Park JY, et al. Outcome of postoperative intratumoral bleomycin injection for cystic craniopharygioma. J Korean Med Sci 2002;17:254-259.
18. Nirenberg D, Harbaugh R, et al. Continuous intratumoral infusion of methotrexate for recurrent glioblastoma: A pilot study. Neurosurgery 1991;28:752-761.
19. Madrid Y, Feigenbaum L, et al. New directions in the delivery of drugs and other substances to the central nervous system. Adv Pharmacol 1991;22:299-321.
20. Merchant RE, Merchant LH, et al. Intralesional infusion of lymphokine- Activated killer (lak) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery 1988;23:725-732.
21. Harbaugh RE, Saunders RL, et al. Use of implantable pumps for central nervous system drug infusions to treat neurological disease. Neurosurgery 1988;23: 693-697.
22. Atkinson LL, Merchant RE, et al. sterile abscesses in glioma patients treated by intraparenchymal injection of lymphokine- Activated killer cells and recombinant interleukin-2: Case reports. Neurosurgery 1989;25:805-809.
23. Merchant RE, Ellison MD, et al. Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. J Neurooncol 1990;8:173-188.
24. Morantz RA, Kimler BF, et al. Bleomycin and brain tumors. J Neurooncol 1983;1: 249-255.
25. Takahashi H, Nakazawa N, et al. Evaluation of postoperative intratumoral injection of bleomycin for craniopharyngioma in children. J Neurosurg 1985;62:120-127.
26. Farkklia M, Jaaskelainen J, et al. Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma. Br J Cancer 1994;70:138-141.
27. Jacobs SK, Wilson DJ, et al. Interleukin-2 or autologous lymphokine- Activated killer cell treatment of malignant glioma: Phase I trial. J Cancer Res 1986;40: 2101-2104.
28. Menei P, Venier MC, et al. Local and sustained delivery of 5-fluoruracil from biodegradable microspheres for the radiosensitization of glioblastoma. Cancer 1999;86:325-330.
29. Menei P, Boisdron-Celle M, et al. Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Neurosurgery 1996;39:117-123.
30. Emerich DF, Tracy MA, et al. Biocompatibility of poly(DL-lactide-co- glycolide) microspheres implanted into the brain. Cell Transplant 1999;8:47-58.
31. Kimler BF, Liu C, et al. Intracerebral chemotherapy in the 9L rat brain tumor model. J Neurooncol 1992;14:191-200.
32. Lum JT, Nguyen T, et al. Drug distribution in solid tissue of the brain following chronic local perfusion utilizing implanted osmotic minipumps. J Pharm Methods 1984;12:141-147.
33. Bouvier G, Penn RD, et al. Direct delivery of medication into a brain tumor through multiple chronically implanted catheters. Neurosurgery 1987;20:286-291.
34. Laske DW, Morrison PF, et al. chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg 1997;87:586-594.
35. Yoshida TK, Shimizu K, et al. Intrathecal chemotherapy with ACNU in a meningeal gliomatosis rat model. J Neurosurg 1992;77:778-782.
36. Penn RD, York MM, et al. Catheter Systems for Intrathecal Drug Delivery. J Neurosurg 1995;83:215-217.
37. Engelhard HH. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surg Neurol 2000;53:458-464.
38. Hlavaty J, Hlubinova K, et al. Treatment of rat gliomas with recombinant retrovirus harboring herpes simplex virus thymidine kinase suicide gene. Neoplasma 1997;44:342-347.
39. Chen SH, Shine HD, et al. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer. Proc Natl Acad Sci USA 1994;91:3054-3057.
40. Vincent AJPE, Vogels R, et al. Herpes simplex virus thymidine kinase gene therapy for rat malignant brain tumors. Hum Gene Ther 1996;7:197-205.
41. Shand N, Weber F, et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene follow by ganciclovir. Hum Gene Ther 1999;10:2325-2335.
42. Ewend MG, Sampath P, et al. Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma. Neurosurgery 1998;43: 1185-1193.
43. Horellou P, Sabate O, et al. Adenovirus-mediated gene transfer to the central nervous system for parkinson's disease. Exp Neurol 1997;144:131-138.
44. Floeth FW, Aulich A, et al. MR imaging and single-photon emission CT findings after gene therapy for human glioblastoma. AJNR 2001;22:1517-1527.
45. Long Z, Li LP, et al. Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells. Hum Gene Ther 1998;9:1165-1172.
46. Ram Z, Culver KW, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997;3:1354-1361.
47. Alemany R, Gomez- Manzano C, et al. Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Experimental Cell Res 1999;252:1-12.
48. Ram Z, Culver KW, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997;3:1354-1361.
49. Laske DW, Morrison PF, et al. Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single photon emission computerized tomography imaging. J Neurosurg 1997;87:586-594.
50. Tamargo RJ, Myseros JS, et al. Interstitial chemotherapy of the 9L gliosarcoma: Controlled release polymers for drug delivery in the brain. Cancer Res 1993;53:329-333.
51. Brem H, Ewend MG, et al. the safety of interstitial chemotherapy with bcnu-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: Phase I trial. J Neurooncol 1995;26:111-123.
52. Valtonen S, Timonen U, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study. Neurosurgery 1997;41:44-49.
53. Rhines, LD, Sampath, P, et al. O6-Benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res 2000;60: 6307-6310.
54. Quinn JA, Pluda J, et al. Phase II trial of carmustine plus O (6)-benzylguanine for patients with nitrosurea-resistant recurrent or progressive malignant glioma. J Clinical Oncology 2002;20:2277-2283.
55. Brem H, Plantadosi S, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995;345:1008-1012.
56. Madrid Y, Langer LF, et al. New directions in the delivery of drugs and other substances to the central nervous system. Adv Pharmacol 1991;22:299-324.
57. Sampath P, Hanes J, et al. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Cancer Res 1999;59:2107-2114.
58. Emerich DF, Bruhn S, et al. Cellular delivery of CFTF but not NT-4/5 prevents degeneration of striatal neurons in a rodent model of Huntington's disease. Cell Transplant 1998;7:213-225.
59. Linder MD, Emerich DF, et al. Therapeutic potential of a polymer-encapsulated L-DOPA and dopamine-producing cell line in rodent and primate models of Parkinson's disease. Cell Transplant 1998;7:165-174.
60. Fleming AB, Saltzman WM, et al. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 2002;41:403-419.
61. Yuan X, Tabassi K, et al. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma. Radiat Oncol Invest 1999;7:218-230.
62. Yuan X, Dillehay LE, et al. IUdR polymers for combined continuous low-dose rate and high-dose rate sensitization of experimental human malignant glioma. Int J Cancer 2001;96:118-125.
63. Bouvier G, Penn RD, et al. Direct delivery of medication into a brain tumor through multiple chronically implanted catheters. Neurosurgery 1987;20:286-291.
64. Lum, JT, Nguyen, T, et al. drug distribution in solid tissue of the brain following chronic perfusion utilizing implanted osmotic minipumps. J Pharmacol Methods 1984;12:141-147.
65. Hendriske NH, Schinkel AH, et al. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacology 1998;124:1413-1418.
66. Emerich DF, Tracy MA, et al. Biocompatibility of poly(DL-lactide-co- glycolide) microspheres implanted into the brain. Cell Transplant 1999;8:47-58.
67. Golumbek PT, Azhari R, et al. controlled release, biodegradable cytokine depots: A new approach in cancer vaccine design. Cancer Res 1993;53:5841-5844.
68. Kaiser MG, Parsa AT, Fine RL, et al. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 2000;47:1391-1399.
69. Laske DW, et al. Tumor regression with regional distribution of the targeted toxin TF-CRM107 I patients with malignant brain tumors. Nat Med 1997;3:1362-1367.
70. Broaddus WC, Prabhu SS, et al. Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchmyal controlled-rate infusion. J Neurosurg 1998;88:734-742.
71. Rand RW, Kreitman RJ, et al. Intratumoral administration of recombinant circularly permutated interleukin-4-pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 2000;6:2157-2165.
72. Heimberger AB, Archer GE, et al. Temozolmide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clin Cancer Res 2001;6:4148-4153.
73. Chen MY, Lonser RR, et al. variables affecting convection enhanced delivery to the striatum: A systemic examination of rate of infusion, cannula size, InfU S ate concentration, and tissue-cannula sealing time. J Neurosurg 1999;90:315-320.
74. Lieberman DM, Laske DW, et al. Convection enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 1995;82:1021-1029.
75. Mardor Y, Roth Y, et al. Monitoring response to convection enhanced taxol delivery in brain tumor patients using diffusions-weighted magnetic resonance imaging. Cancer Res 2001;1:4971-4973.
76. Bobo RH, Laske DW, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994;91:2076-2080.
77. Prabhu SS, Broaddus WC, et al. Distribution of macromolecular dyes in brain using positive pressure infusion: A model for direct controlled delivery of therapeutic agents. Surg Neurol 1998;50:367-375.
78. Nirenberg D, Harbaugh R, et al. Continuous infusion of methotrexate for recurrent glioblastoma: A pilot study. Neurosurgery 1991;28:752-761.
79. Morrison, PF, Laske, DW, et al. High-flow microinfusion: Tissue penetration and pharmacodynamics. Am J of Physiology 1994;266:R292-R305.
80. Groothuis DR, Ward S, et al. Comparison of 14C- Sucrose delivery to the brain by intravenous, intraventricular, and convection-enhanced intracerebral infusion. J Neurosurg 1999;90:321-331.
81. Viola JJ, Agbaria R, et al. In situ cyclopentenyl cytosine infusion for the treatment of experimental brain tumors. Cancer Res 1995;55:1306-1309.
82. Geer CP, Grossman SA. Interstitial fluid flow along white matter tracts: A potentially important mechanism for the dissemination of primary brain tumors. J Neurooncol 1997;32:193-201.
83. Kroll RA, Pagel MA, et al. Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery 1996;38:746-753.
84. Wood JD, Lonser RR, et al. Convective delivery of macromolecules into the naïve and traumatized spinal cords of rats. J Neurosurg (Spine I) 1999;90:115-120.
85. Lonser RR, Gogate N, et al. Direct convective delivery of macromolecules to the spinal cord. J Neurosurg 1998;89:616-622.
86. Sandberg DI, Edgar MA, et al. Convection-enhanced delivery into the rat brainstem. J Neurosurg 2002;96:885-891.
87. Nutt JG., Burchiel KJ., et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003;60:69-73.
88. de Lange ECM, de Boer BAG, et al. Microdialysis for pharmacokinetic analysis of drug transport to the brain. Adv Drug Dev Rev 1999;36:211-227.
89. Engelhard HH, Duncan HA, et al. Therapeutic effects of sodium butyrate on glioma cells in vitro and in the rat C6 glioma model. Neurosurgery 2001;48:616-625.
90. Kimler BF, Liu C, et al. Intracerebral chemotherapy in the 9L rat brain tumor model. J Neurooncol 1992;14:191-200.
91. Kikuchi T, Akasaki Y., et al. Antitumor activity of interleukin-18 on mouse glioma cells. J Immunother 2000;23:184-189.
92. Miller CR, Williams CR, et al. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res 2002;62:773-780.
93. Schinkel AH. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999;36:179-194.
94. Bruce JN, Falavigna A, et al. Intracerebral clysis in a rat glioma model. Neurosurgery 2000;46:683-691.
95. Ram Z, Culver KW, et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1997;53:83-88.
96. Lieberman DM, Corthesy ME, et al. Reversal of experimental parkinsonism by using selective chemical ablation of the medial globus pallidus. J Neurosurg 1999; 90:928-934.
97. Tamai I, Tsuji A. Drug delivery through the blood-brain barrier. Adv Drug Deliv Rev 1996;19:401-424.